A Randomized, Double-Blind, Active Comparator-Controlled Phase III Trial to Evaluate the Immunogenicity and Safety of the Group ACYW135 Meningococcal Conjugate Vaccine in Population Aged 3 to 5 Months
Latest Information Update: 07 Apr 2026
At a glance
- Drugs ACYW135X-meningococcal-conjugate-vaccine-Sinovac-Biotech (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate
- Indications Meningococcal infections
- Focus Registrational; Therapeutic Use
- Sponsors Sinovac Biotech
Most Recent Events
- 07 Apr 2026 New trial record